Literature DB >> 17296653

Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains.

Jillian Dormandy1, Akos Somoskovi, Barry N Kreiswirth, Jeffrey R Driscoll, David Ashkin, Max Salfinger.   

Abstract

BACKGROUND: Mycobacterium tuberculosis strains belonging to the W-Beijing family have received broad clinical and public health attention because of their rapid worldwide spread and their frequent association with outbreaks, multidrug resistance, and treatment failures and relapses.
METHODS: The present study examined a large number of multidrug-resistant strain-W isolates (isolates of 29 patients) by susceptibility testing for pyrazinamide (PZA) using the reference BACTEC 460TB method (Becton Dickinson Diagnostic Instrument Systems; Sparks, MD) and also by DNA sequencing of the pncA gene.
RESULTS: We found that despite of the presence of a strain W-specific Thr47Ala in the pncA gene, all strains showed susceptibility to PZA in the reference BACTEC 460TB system due to their higher minimum inhibitory concentrations (relative to BACTEC 460TB PZA-susceptible strains).
CONCLUSIONS: Our results suggest that the current radiometric reference method cannot reproducibly detect PZA resistance in patients infected with W-Beijing strains. Therefore, PZA susceptibility testing should instead be based on analysis of the pncA gene for resistance-associated mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17296653     DOI: 10.1378/chest.06-1899

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  12 in total

1.  Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.

Authors:  Molly F Franke; Mercedes C Becerra; Dylan B Tierney; Michael L Rich; Cesar Bonilla; Jaime Bayona; Megan M McLaughlin; Carole D Mitnick
Journal:  Ann Am Thorac Soc       Date:  2015-05

Review 2.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

3.  Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.

Authors:  Gustavo E Velásquez; Roger I Calderon; Carole D Mitnick; Mercedes C Becerra; Chuan-Chin Huang; Zibiao Zhang; Carmen C Contreras; Rosa M Yataco; Jerome T Galea; Leonid W Lecca; Megan B Murray
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Authors:  J Werngren; E Sturegård; P Juréen; K Ängeby; S Hoffner; T Schön
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

Review 5.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis.

Authors:  Karolien Stoffels; Vanessa Mathys; Maryse Fauville-Dufaux; René Wintjens; Pablo Bifani
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

7.  Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City.

Authors:  Dawn Verdugo; Dorothy Fallows; Shama Ahuja; Neil Schluger; Barry Kreiswirth; Barun Mathema
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

8.  Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.

Authors:  Pontus Juréen; Jim Werngren; Juan-Carlos Toro; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

9.  Rapid colorimetric testing for pyrazinamide susceptibility of M. tuberculosis by a PCR-based in-vitro synthesized pyrazinamidase method.

Authors:  Man Zhou; Xuelei Geng; Jun Chen; Xude Wang; Dianbing Wang; Jiaoyu Deng; Zhiping Zhang; Weihua Wang; Xian-En Zhang; Hongping Wei
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

10.  Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.

Authors:  Glenn P Morlock; Frances C Tyrrell; Dorothy Baynham; Vincent E Escuyer; Nicole Green; Youngmi Kim; Patricia A Longley-Olson; Nicole Parrish; Courtney Pennington; Desmond Tan; Brett Austin; James E Posey
Journal:  Tuberc Res Treat       Date:  2017-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.